Confronting convention
We take risks and challenge the status quo because disease must be fought with unexpected practice.
Unlike traditional therapeutic approaches that target growth factors in their active states, Scholar Rock uses its technology platform and structural insights to discover new medicines designed to selectively target the precursor, or inactive, forms of growth factors with the aim of avoiding toxicity and improving efficacy.
Learn About Our ScienceScholar Rock works across therapeutic areas and shines new light on the overlooked to better target disease.
Our growing team is replete with good people who eat, sleep, and breathe good science. We promote a spirit of inquiry outside one’s traditional expertise to uncover enlightened solutions for patients.
Exploration
Our Growing Pipeline
Follow our product candidates on their journeys to fighting serious diseases.
Spinal Muscular Atrophy
Apitegromab
(SRK-015)
Inhibit the activation of latent myostatin to promote a potentially clinically-beneficial increase in muscle function
Oncology
SRK-181
Potential to overcome primary resistance to checkpoint inhibitors to reach a larger patient population
Fibrosis
Inhibit TGFβ signaling to potentially offer a powerful new approach to suppressing pro-fibrotic signaling in multiple organs
Iron-Restricted Anemias
Target RGMc—a co-receptor of BMP6—to potentially treat diseases associated with dysregulation of iron metabolism
September 22, 2022
Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 20, 2022
Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer
September 16, 2022
Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit
Events
View More EventsLet’s Connect
Let’s talk science, let’s talk you! We’d love to hear from you and answer any questions you may have.
Join Our Team
We’re a group of thinkers and doers who fight disease from a new angle.